EnBiotix, Inc., a Cambridge, MA-based product-focused bioengineering company, completed a Series A funding of undisclosed amount.
Backers included Wired Holdings Investment Corp. and Apeiron Holdings Limited. In conjunction with the funding, WHIC and EnBiotix entered into an agreement to establish a new joint venture company in Brazil, EnBiotix (Brasil) Ltda., to develop and commercialize the company’s product portfolio throughout Latin America.
Roberto Guttman, Founder and CEO of Wired Holdings, has joined EnBiotix’ Board of Directors.
Under the terms of the agreement, WHIC will provide strategic, regulatory and commercial assistance to EnBiotix in establishing and implementing EBL while EnBiotix, Inc. will continue to retain all rights to the compounds outside of Latin America and responsibility for continuing development of all products. EBL will initially focus on the products EBX-001 for P. aeuriginosa infections in cystic fibrosis (CF), non-CF bronchiectasis and chronic obstructive pulmonary disease patients; EBX-002 for catheter-associated urinary tract infections; and EPP-001 which addresses prosthetic joint infections.
Led by Jeffrey D. Wager, M.D., Chairman and CEO, EnBiotix deploys novel systems and synthetic biology technologies developed by Prof. James J. Collins, the Termeer Professor of Medical Engineering & Science Professor, Department of Biological Engineering, Massachusetts Institute of Technology.
The most advanced products are:
– EBX-001, which combines tobramycin with a metabolite potentiator as a novel, inhaled investigational treatment for P. aeruginosa infections in cystic fibrosis (CF), non-CF bronchiectasis and COPD patients.
– About EBX-002, a proprietary aminoglycoside + potentiator IV Piggyback in development for gram-negative catheter-associated urinary tract infections (caUTIs) in the hospital setting.
– EPP-001, an engineered bacteriophage using customized phages coding for biofilm-degrading enzyme payloads.